Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | TNK2 | Q07912 | 14/20 | 0.46 |
| ▸ | BTK | Q06187 | 4/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241497 | 0.91 | RAF1 (0.47) | RAF1SRCTNK2BTKIGF1R | |
| SCHEMBL8399399 | 0.88 | RAF1 (0.45) | RAF1SRCTNK2BTK | |
| SCHEMBL10242091 | 0.88 | TNK2 (0.51) | RAF1SRCTNK2BTKIGF1R | |
| SCHEMBL8400148 | 0.88 | BTK (0.54) | RAF1SRCTNK2BTKIGF1R | |
| SCHEMBL10241498 | 0.88 | RAF1 (0.46) | RAF1SRCTNK2BTK | |
| SCHEMBL10240965 | 0.87 | TNK2 (0.48) | RAF1SRCTNK2BTKIGF1R | |
| SCHEMBL8399662 | 0.86 | TNK2 (0.49) | RAF1SRCTNK2BTKIGF1R | |
| SCHEMBL8399681 | 0.85 | BTK (0.44) | RAF1SRCTNK2BTKIGF1R | |
| SCHEMBL8401978 | 0.85 | RAF1 (0.47) | RAF1SRCTNK2BTKIGF1R | |
| SCHEMBL8400172 | 0.85 | RAF1 (0.43) | RAF1SRCTNK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114846-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | EGFR, ERBB2, RICTOR | RAF1 244/4885SRC 12/4885TNK2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.